Vijayalakshmi Nandakumar
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antiphospholipid Syndrome | 4 | 2025 | 37 | 2.860 |
Why?
| Antibodies, Antiphospholipid | 4 | 2025 | 26 | 2.280 |
Why?
| Enzyme-Linked Immunosorbent Assay | 6 | 2025 | 833 | 1.880 |
Why?
| Antibodies, Anticardiolipin | 2 | 2025 | 8 | 1.190 |
Why?
| Anti-Citrullinated Protein Antibodies | 2 | 2024 | 109 | 1.050 |
Why?
| Immunoglobulin G | 4 | 2025 | 847 | 1.030 |
Why?
| Arthritis, Rheumatoid | 2 | 2024 | 1092 | 0.970 |
Why?
| Complement Membrane Attack Complex | 1 | 2025 | 37 | 0.950 |
Why?
| Complement Activation | 2 | 2025 | 376 | 0.950 |
Why?
| 14-3-3 Proteins | 1 | 2024 | 17 | 0.940 |
Why?
| Vimentin | 1 | 2024 | 51 | 0.910 |
Why?
| Synovitis | 1 | 2024 | 24 | 0.880 |
Why?
| Transglutaminases | 1 | 2023 | 153 | 0.820 |
Why?
| Autoantibodies | 3 | 2024 | 1466 | 0.770 |
Why?
| Sensitivity and Specificity | 5 | 2025 | 1838 | 0.760 |
Why?
| Complement System Proteins | 1 | 2025 | 313 | 0.760 |
Why?
| Enzyme Assays | 1 | 2021 | 25 | 0.750 |
Why?
| Body Fluids | 1 | 2021 | 63 | 0.740 |
Why?
| Endopeptidases | 4 | 2014 | 87 | 0.730 |
Why?
| Pneumocystis | 2 | 2020 | 11 | 0.720 |
Why?
| Antibodies, Viral | 2 | 2022 | 601 | 0.700 |
Why?
| Celiac Disease | 1 | 2023 | 286 | 0.690 |
Why?
| Diagnostic Tests, Routine | 1 | 2021 | 102 | 0.690 |
Why?
| Clinical Chemistry Tests | 1 | 2020 | 11 | 0.680 |
Why?
| Hydrogen-Ion Concentration | 1 | 2021 | 544 | 0.670 |
Why?
| Immunoassay | 1 | 2020 | 107 | 0.650 |
Why?
| Adrenocorticotropic Hormone | 1 | 2020 | 133 | 0.650 |
Why?
| Antibodies, Neutralizing | 1 | 2021 | 265 | 0.630 |
Why?
| Anticarcinogenic Agents | 2 | 2011 | 77 | 0.620 |
Why?
| Plasma | 1 | 2020 | 206 | 0.600 |
Why?
| Tumor Burden | 1 | 2019 | 286 | 0.570 |
Why?
| Macrophages, Alveolar | 2 | 2020 | 389 | 0.570 |
Why?
| Epigenesis, Genetic | 4 | 2014 | 613 | 0.530 |
Why?
| Early Detection of Cancer | 1 | 2021 | 370 | 0.520 |
Why?
| Immunocompromised Host | 2 | 2020 | 198 | 0.520 |
Why?
| Macrophage Activation | 1 | 2017 | 189 | 0.500 |
Why?
| DNA Methylation | 2 | 2011 | 607 | 0.500 |
Why?
| Mutation | 4 | 2024 | 3717 | 0.460 |
Why?
| Genes, p16 | 2 | 2011 | 19 | 0.450 |
Why?
| Pneumonia, Pneumocystis | 3 | 2020 | 35 | 0.440 |
Why?
| Rheumatoid Factor | 2 | 2024 | 167 | 0.420 |
Why?
| Skin Neoplasms | 2 | 2011 | 825 | 0.420 |
Why?
| Prostatic Neoplasms | 1 | 2021 | 1016 | 0.410 |
Why?
| Immunoglobulin M | 2 | 2025 | 275 | 0.410 |
Why?
| Adaptive Immunity | 1 | 2013 | 161 | 0.390 |
Why?
| Reproducibility of Results | 3 | 2025 | 3083 | 0.380 |
Why?
| ROC Curve | 2 | 2025 | 503 | 0.370 |
Why?
| Genes, Suppressor | 1 | 2010 | 5 | 0.360 |
Why?
| Humans | 25 | 2025 | 129622 | 0.360 |
Why?
| Catechin | 1 | 2011 | 24 | 0.350 |
Why?
| Histones | 4 | 2014 | 588 | 0.350 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2010 | 71 | 0.340 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 117 | 0.340 |
Why?
| Killer Cells, Natural | 1 | 2013 | 427 | 0.340 |
Why?
| Gene Silencing | 1 | 2010 | 190 | 0.330 |
Why?
| Neoplasms | 2 | 2019 | 2470 | 0.330 |
Why?
| Lectins, C-Type | 3 | 2020 | 71 | 0.310 |
Why?
| Pneumocystis carinii | 2 | 2020 | 10 | 0.310 |
Why?
| Biomarkers | 3 | 2025 | 3973 | 0.310 |
Why?
| Biopsy | 2 | 2023 | 1097 | 0.300 |
Why?
| Proanthocyanidins | 1 | 2008 | 10 | 0.300 |
Why?
| Ultraviolet Rays | 1 | 2010 | 383 | 0.290 |
Why?
| Antineoplastic Agents | 1 | 2019 | 2061 | 0.280 |
Why?
| Retrospective Studies | 4 | 2025 | 14519 | 0.260 |
Why?
| Plant Extracts | 1 | 2008 | 199 | 0.260 |
Why?
| beta 2-Glycoprotein I | 1 | 2025 | 4 | 0.240 |
Why?
| Aged | 6 | 2025 | 22099 | 0.230 |
Why?
| Lupus Coagulation Inhibitor | 1 | 2024 | 5 | 0.220 |
Why?
| Prothrombin | 1 | 2024 | 20 | 0.220 |
Why?
| Gliadin | 1 | 2023 | 13 | 0.220 |
Why?
| Phosphatidylserines | 1 | 2024 | 88 | 0.210 |
Why?
| Reference Values | 1 | 2025 | 793 | 0.210 |
Why?
| Serine | 1 | 2024 | 138 | 0.210 |
Why?
| Liver Cirrhosis, Biliary | 1 | 2023 | 18 | 0.210 |
Why?
| Middle Aged | 6 | 2025 | 31150 | 0.200 |
Why?
| Immunoglobulin A | 1 | 2023 | 200 | 0.200 |
Why?
| Adult | 6 | 2025 | 35572 | 0.190 |
Why?
| Amylases | 1 | 2021 | 17 | 0.190 |
Why?
| Ubiquitin-Specific Proteases | 4 | 2014 | 9 | 0.190 |
Why?
| L-Lactate Dehydrogenase | 1 | 2021 | 119 | 0.190 |
Why?
| Lipase | 1 | 2021 | 66 | 0.180 |
Why?
| Sequence Analysis, DNA | 2 | 2014 | 779 | 0.180 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 2 | 2011 | 17 | 0.180 |
Why?
| Kallikreins | 1 | 2021 | 29 | 0.180 |
Why?
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2011 | 32 | 0.180 |
Why?
| Cohort Studies | 2 | 2021 | 5420 | 0.180 |
Why?
| CARD Signaling Adaptor Proteins | 1 | 2020 | 19 | 0.170 |
Why?
| Epidemics | 1 | 2021 | 82 | 0.170 |
Why?
| Prostate-Specific Antigen | 1 | 2021 | 162 | 0.170 |
Why?
| Cell Differentiation | 4 | 2020 | 1902 | 0.160 |
Why?
| Predictive Value of Tests | 1 | 2025 | 1952 | 0.160 |
Why?
| Female | 10 | 2025 | 68770 | 0.160 |
Why?
| Male | 8 | 2025 | 63674 | 0.160 |
Why?
| Trans-Activators | 4 | 2014 | 388 | 0.150 |
Why?
| Mutation, Missense | 3 | 2014 | 317 | 0.150 |
Why?
| Temperature | 1 | 2020 | 636 | 0.140 |
Why?
| Diagnosis, Differential | 1 | 2021 | 1434 | 0.130 |
Why?
| Adoptive Transfer | 1 | 2017 | 218 | 0.130 |
Why?
| Animals | 9 | 2020 | 35360 | 0.120 |
Why?
| Mortality | 1 | 2017 | 307 | 0.120 |
Why?
| Rats | 3 | 2020 | 5499 | 0.120 |
Why?
| Myeloid Progenitor Cells | 1 | 2014 | 17 | 0.120 |
Why?
| Membrane Proteins | 2 | 2020 | 1119 | 0.110 |
Why?
| HEK293 Cells | 2 | 2014 | 697 | 0.110 |
Why?
| Genes, p53 | 1 | 2014 | 70 | 0.110 |
Why?
| Gastrointestinal Stromal Tumors | 1 | 2014 | 46 | 0.110 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 68 | 0.110 |
Why?
| Inhibitor of Differentiation Protein 2 | 1 | 2013 | 5 | 0.110 |
Why?
| Interleukin-3 | 1 | 2013 | 23 | 0.110 |
Why?
| Host-Pathogen Interactions | 1 | 2017 | 352 | 0.110 |
Why?
| Proto-Oncogene Proteins | 2 | 2014 | 638 | 0.110 |
Why?
| Gastrointestinal Neoplasms | 1 | 2014 | 72 | 0.110 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2014 | 511 | 0.100 |
Why?
| Stomach Neoplasms | 1 | 2014 | 99 | 0.100 |
Why?
| Chromatin Immunoprecipitation | 1 | 2013 | 132 | 0.100 |
Why?
| Mice, Knockout | 3 | 2017 | 2871 | 0.100 |
Why?
| ras Proteins | 1 | 2014 | 144 | 0.100 |
Why?
| Transduction, Genetic | 1 | 2013 | 128 | 0.100 |
Why?
| Immunoblotting | 1 | 2013 | 305 | 0.100 |
Why?
| Flow Cytometry | 2 | 2014 | 1156 | 0.100 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 331 | 0.100 |
Why?
| Mice | 6 | 2020 | 16937 | 0.100 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 359 | 0.100 |
Why?
| Biomarkers, Tumor | 1 | 2019 | 1181 | 0.100 |
Why?
| Dendritic Cells | 1 | 2014 | 478 | 0.090 |
Why?
| Mice, Hairless | 1 | 2010 | 60 | 0.090 |
Why?
| ErbB Receptors | 1 | 2014 | 607 | 0.090 |
Why?
| Hydroxamic Acids | 1 | 2011 | 88 | 0.090 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 381 | 0.080 |
Why?
| Acetylation | 1 | 2011 | 246 | 0.080 |
Why?
| Chromatin Assembly and Disassembly | 1 | 2010 | 101 | 0.080 |
Why?
| Gene Expression Profiling | 1 | 2017 | 1706 | 0.080 |
Why?
| Gene Expression Regulation | 2 | 2017 | 2548 | 0.080 |
Why?
| Cell Cycle | 2 | 2013 | 592 | 0.080 |
Why?
| Azacitidine | 1 | 2011 | 139 | 0.080 |
Why?
| Macrophages | 1 | 2017 | 1480 | 0.080 |
Why?
| Histone Deacetylases | 1 | 2011 | 212 | 0.080 |
Why?
| DNA Mutational Analysis | 3 | 2014 | 387 | 0.080 |
Why?
| Transcriptional Activation | 1 | 2011 | 366 | 0.080 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2008 | 15 | 0.080 |
Why?
| Tumor Suppressor Proteins | 1 | 2010 | 317 | 0.070 |
Why?
| Biological Availability | 1 | 2008 | 147 | 0.070 |
Why?
| Grape Seed Extract | 1 | 2008 | 44 | 0.070 |
Why?
| Adenocarcinoma | 1 | 2014 | 898 | 0.070 |
Why?
| Transcription Factors | 2 | 2013 | 1651 | 0.070 |
Why?
| Child, Preschool | 1 | 2021 | 10518 | 0.070 |
Why?
| Disease Models, Animal | 1 | 2017 | 4063 | 0.070 |
Why?
| B-Lymphocytes | 1 | 2011 | 815 | 0.060 |
Why?
| MAP Kinase Signaling System | 1 | 2008 | 312 | 0.060 |
Why?
| Young Adult | 1 | 2021 | 12426 | 0.060 |
Why?
| NF-kappa B | 1 | 2008 | 653 | 0.060 |
Why?
| Apoptosis | 2 | 2013 | 2503 | 0.050 |
Why?
| Clinical Trials as Topic | 1 | 2008 | 1004 | 0.050 |
Why?
| Cell Line, Tumor | 1 | 2011 | 3215 | 0.050 |
Why?
| Exons | 2 | 2014 | 342 | 0.050 |
Why?
| Antibodies, Antinuclear | 1 | 2023 | 66 | 0.050 |
Why?
| Adolescent | 1 | 2021 | 20391 | 0.050 |
Why?
| Mice, Inbred C57BL | 3 | 2020 | 5440 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2014 | 2142 | 0.050 |
Why?
| Child | 1 | 2021 | 20882 | 0.050 |
Why?
| Lung Neoplasms | 1 | 2014 | 2344 | 0.050 |
Why?
| Colony Count, Microbial | 1 | 2020 | 118 | 0.040 |
Why?
| Peroxidase | 1 | 2020 | 174 | 0.040 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 135 | 0.040 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2020 | 312 | 0.040 |
Why?
| Promoter Regions, Genetic | 2 | 2014 | 1207 | 0.040 |
Why?
| Biomedical Research | 1 | 2023 | 638 | 0.040 |
Why?
| Syk Kinase | 1 | 2017 | 21 | 0.030 |
Why?
| Mice, Transgenic | 2 | 2013 | 2119 | 0.030 |
Why?
| RAW 264.7 Cells | 1 | 2017 | 49 | 0.030 |
Why?
| Protein Binding | 2 | 2014 | 2121 | 0.030 |
Why?
| Rats, Inbred Strains | 1 | 2017 | 368 | 0.030 |
Why?
| Mitochondria | 1 | 2023 | 877 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2020 | 1198 | 0.030 |
Why?
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 9 | 0.030 |
Why?
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 15 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2017 | 587 | 0.030 |
Why?
| Mutation Rate | 1 | 2014 | 25 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2014 | 88 | 0.030 |
Why?
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 46 | 0.030 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 81 | 0.030 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 147 | 0.030 |
Why?
| GATA2 Transcription Factor | 1 | 2013 | 14 | 0.030 |
Why?
| Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 33 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2014 | 285 | 0.030 |
Why?
| Gene Frequency | 1 | 2014 | 503 | 0.030 |
Why?
| Genetic Loci | 1 | 2014 | 275 | 0.030 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 259 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2014 | 7084 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2014 | 360 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 958 | 0.020 |
Why?
| Cytokines | 1 | 2020 | 2017 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 857 | 0.020 |
Why?
| Gene Deletion | 1 | 2013 | 379 | 0.020 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 116 | 0.020 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 487 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2014 | 1295 | 0.020 |
Why?
| Cell Survival | 1 | 2013 | 1086 | 0.020 |
Why?
| Cell Lineage | 1 | 2011 | 333 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 237 | 0.020 |
Why?
| Homeostasis | 1 | 2013 | 611 | 0.020 |
Why?
| Gene Expression | 1 | 2014 | 1472 | 0.020 |
Why?
| Lung | 1 | 2020 | 3931 | 0.020 |
Why?
| Cells, Cultured | 1 | 2014 | 4083 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2014 | 2073 | 0.020 |
Why?
| DNA-Binding Proteins | 1 | 2013 | 1443 | 0.020 |
Why?
| Cell Proliferation | 1 | 2013 | 2391 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2014 | 2282 | 0.020 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1052 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2011 | 1418 | 0.020 |
Why?
| Signal Transduction | 1 | 2017 | 4925 | 0.010 |
Why?
|
|
Nandakumar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|